Biocomparison of three formulations of the S1P1 receptor modulator ponesimod in healthy subjects

Drugs in R and D

Volumn 15, Issue 2, 2015, Pages 203-210

  Juif, Pierre Eric ^a   Hoch, Matthias ^a   D’Ambrosio, Daniele ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PONESIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; MICROCAPSULE; TABLET; THIAZOLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL LABORATORY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ELECTROCARDIOGRAM; ELIMINATION RATE CONSTANT; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HALF LIFE TIME; HEADACHE; HEART RATE; HUMAN; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MICROCAPSULE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PR INTERVAL; PRIORITY JOURNAL; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SINUS BRADYCARDIA; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; ADMINISTRATION AND DOSAGE; BIOAVAILABILITY; MEDICINAL CHEMISTRY; METABOLISM; PHARMACOKINETICS; PROCEDURES; TABLET; THERAPEUTIC EQUIVALENCE;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; RECEPTORS, LYSOSPHINGOLIPID; TABLETS; THERAPEUTIC EQUIVALENCY; THIAZOLES;

EID: 84973252221     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-015-0095-7     Document Type: Article

References (20)

1. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1- phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8(10):753–63.
2. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4(5):397–407.
3. Takuwa Y, Okamoto Y, Yoshioka K, Takuwa N. Sphingosine-1- phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta. 2008;1781(9):483–8.
4. Bigaud M, Guerini D, Billich A, Bassilana F, Brinkmann V. Second generation S1P pathway modulators: research strategies and clinical developments. Biochim Biophys Acta. 2014;1841(5):745–58.
5. Thangada S, Khanna KM, Blaho VA, Oo ML, Im DS, Guo C, et al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med. 2010;207(7):1475–83.
6. Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, et al. 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem. 2010;53(10):4198–211.
7. Vaclavkova A, Chimenti S, Arenberger P, Hollo P, Sator PG, Burcklen M, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;384(9959):2036–45.
8. Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014;85(11):1198–208.
9. Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-inhuman study. Br J Clin Pharmacol. 2013;76(6):888–96.
10. Brossard P, Scherz M, Halabi A, Maatouk H, Krause A, Dingemanse J. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol. 2014;54(2):179–88.
11. Hoch M, D’Ambrosio D, Wilbraham D, Brossard P, Dingemanse J. Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects. Eur J Pharm Sci. 2014;63C:147–53.
12. Reyes M, Brossard P, Chassard D, Hoch M, Dingemanse J. Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive. Eur J Clin Pharmacol. 2014;70(3):287–93.
13. Reyes M, Hoch M, Brossard P, Wagner-Redeker W, Miraval T, Dingemanse J. Mass balance, pharmacokinetics and metabolism of the selective S1P receptor modulator ponesimod in humans. Xenobiotica. 2015;45(2):139–49.
14. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1982.
15. Poorjavad M, Derakhshandeh F, Etemadifar M, Soleymani B, Minagar A, Maghzi AH. Oropharyngeal dysphagia in multiple sclerosis. Mult Scler. 2010;16(3):362–5.
16. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42(2):107–21.
17. Krause A, Brossard P, D’Ambrosio D, Dingemanse J. Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator. J Pharmacokinet Pharmacodyn. 2014;41(3):261–78.
18. Schmouder R, Hariry S, David OJ. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol. 2012;68(4):355–62.
19. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.
20. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.